Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009
Date:7/14/2009

expansion stage of the trial, which will enroll a total of 46 advanced breast cancer patients overall.
  • Reported that in a Phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel in non-small cell lung cancer (NSCLC) patients with locally advanced or metastatic disease, 11 of 17, or almost 65% of evaluable patients in the initial cohort, achieved an objective tumor response according to RECIST criteria. These early results, which exceeded the pre-specified endpoint needed to expand the trial, compare very favorably with historical data with chemotherapy alone and are especially encouraging in this hard-to-treat cancer. Patient enrollment and dosing are continuing in the expansion stage of the trial, which will enroll a total of 49 NSCLC patients overall.
  • Completed patient enrollment in a Phase I trial evaluating bavituximab as monotherapy in patients with advanced refractory cancers. At the 2009 ASCO Annual Meeting, study researchers reported that bavituximab had demonstrated a predictable pharmacokinetic profile and acceptable safety, and that a maximum tolerated dose was not reached, even at the highest planned dose level.
  • Announced that the ASCO Research Foundation awarded one of its 2009 Career Development Awards to a researcher at the University of Texas Southwestern Medical Center for a study of the biologic effects of bavituximab and chemotherapy in patients with advanced lung cancer.
  • Presented data from two studies at the AACR 2009 Annual Meeting providing further confirmation of the unique immunomodulatory mechanisms contributing to the anti-tumor activity of Peregrine's anti-PS antibody platform.
  • Bavituximab Anti-Viral Program

    The company continued to advance the bavituximab anti-viral program:

    • Received major validation of the broad anti-viral potential of the company's anti-PS antib
      '/>"/>

    SOURCE Peregrine Pharmaceuticals, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

    Related medicine news :

    1. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
    2. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
    3. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
    4. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
    5. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
    6. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
    7. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
    8. Peregrine Pharmaceuticals to Report Third Quarter FY 2009 Financial Results
    9. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
    10. Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program
    11. ASCO Research Foundation Grant Will Support Study of Peregrines Bavituximab in Lung Cancer
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/31/2014)... INDIANAPOLIS -- A class of medications previously linked ... to negatively affect their physical functioning according to ... University Center for Aging Research, the University of ... , In a systemic review of more than ... drugs with anticholinergic properties, they report that these ...
    (Date:7/31/2014)... Washington, D.C. July 31, 2014Today the Elizabeth Glaser ... announced a new partnership that will expedite the ... to health facilities in two districts of the ... partnership between EGPAF and Riders for Health will ... laboratory samples and address a critical bottleneck in ...
    (Date:7/31/2014)... school researchers hope to drastically increase the number ... trials, a critical step in testing and developing ... a lack of awareness that clinical testing existsless ... in trials of experimental therapies. , As many ... still don,t enroll, according to the study,s investigators, ...
    (Date:7/31/2014)... Controlled application of vacuum pressure is a promising ... (TBI), suggests an experimental study in the August issue ... the Congress of Neurological Surgeons . The journal ... a part of Wolters Kluwer Health . ... the injured area of the brainshows promise as a ...
    (Date:7/31/2014)... New Delhi, India (PRWEB) July 31, 2014 ... company, has launched a new service named ‘Remove Bad ... against which bad reviews are published on various review ... study about the world of internet marketing, the sites ... by its competitors in order to tailor the service. ...
    Breaking Medicine News(10 mins):Health News:Common drugs adversely impair older adults' physical as well as cognitive functioning 2Health News:Elizabeth Glaser Pediatric AIDS Foundation partners with Riders for Health in Malawi 2Health News:$1.6 million NCI grant to CWRU trains nurses to increase participation in clinical trials 2Health News:$1.6 million NCI grant to CWRU trains nurses to increase participation in clinical trials 3Health News:Vacuum treatment may limit damage after traumatic brain injury 2Health News:Reputation Management India Launches a New Service Called ‘Remove Bad Reviews’ 2
    ... ... defined, animal-protein free maintenance medium for human embryonic and induced pluripotent stem cells. ... Vancouver, BC (PRWEB) ... the release of TeSR™2 , a defined, animal-protein free maintenance medium for human ...
    ... CARMEL, Ind., Oct. 13 Conseco, Inc. (NYSE: CNO ... to ensure that all investors have equal access to information, ... 5:30 p.m. on Tuesday, October 13, 2009. The materials ... exhibits that Conseco will submit to the Securities Exchange Commission ...
    ... Porpoise Evans, a litigation associate in the Miami office of ... among the "40 Under 40" outstanding lawyers of Miami-Dade County ... be honored at the CFF benefit dinner on November 20, ... as one of Miami-Dade County,s top up-and-coming young lawyers is ...
    ... WASHINGTON, Oct. 13 America,s Health Insurance Plans (AHIP) ... today on passage of health care reform legislation in ... bipartisan health care reform that covers all Americans, improves ... affordable, sustainable path. Health plans have proposed guaranteed ...
    ... the following statement today from Executive Vice President ... approval today of historic health care reform legislation ... coordinated health benefits and quality focused coverage as ... chronically-ill and underserved Medicare recipients." , ...
    ... more pre-term infants survive, doctors see more babies with ... News) -- Increased survival of extremely pre-term infants has ... problems caused by abnormal development of blood vessels in ... looked at data on 506 extremely pre-term infants (born ...
    Cached Medicine News:Health News:STEMCELL Technologies Inc. Announces Release of Defined, Animal-Protein Free Maintenance Medium for hESCs and hiPSCs 2Health News:Conseco Announces Availability of Important Information on its Website 2Health News:Cystic Fibrosis Foundation Names Greenberg Traurig Attorney D. Porpoise Evans Among the '40 Under 40' Outstanding Lawyers of Miami-Dade County 2Health News:AHIP Statement on Passage of Senate Finance Committee Legislation 2Health News:XLHealth Applauds Quality Focused Reforms in Senate Finance Committee Legislation 2Health News:Eye Problems Increasing in Preemies 2
    (Date:7/31/2014)... 31, 2014  Zacks.com announces the list of stocks featured ... analysts discuss the latest news and events impacting stocks and ... Biogen (Nasdaq: BIIB - Free Report ), Gilead (Nasdaq: ... PBYI - Free Report ), AbbVie (NYSE: ABBV - ... Report ). Today, Zacks is promoting its ,Buy, ...
    (Date:7/31/2014)... and LONDON , July 31, 2014 ... and services provider for the medical industries, announced today the incorporation ... The United Kingdom has one of the ... USD 8.9 billion in 2012 and it is projected to increase ... at USD 234 billion in 2012, equal to 9.5% of GDP. ...
    (Date:7/31/2014)... -- For the first time, cardiac surgeons, medical professionals ... SynCardia temporary Total Artificial Heart in a peer reviewed ... Journal of Visualized Experiments website. ... SynCardia Total Artificial Heart implantation   goo.gl/2OZyKW ... SynCardia Total Artificial Heart," a July 18, 2014 paper ...
    Breaking Medicine Technology:The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 2The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 3The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 4The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 5The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 6genae Opens Offices in London 2How to Implant the SynCardia Total Artificial Heart Detailed in Peer Reviewed Paper and Matching Video 2How to Implant the SynCardia Total Artificial Heart Detailed in Peer Reviewed Paper and Matching Video 3
    The Columbus microplate strip washer is for individual strips or whole plates.Programming and control are via an alphanumeric display. Up to 30 methods are stored for easy recall....
    ... 96PW washes all 96 wells ... automatically. Separate wash and aspiration ... excellent washing ability. Pre-programmed automatic ... removable 96-channel head reduce maintenance ...
    Easy to use , Allow for a flexible washing , Uniform and efficient , Very robust and reliable , Adjustable to all well shapes , Rack included (not autoclavable) , Autoclavable at 121C , No e...
    ... SkanWasher 300 with a ... Vacuum pressure and aspiration ... are adjustable. On-board software ... 8 different programs. External ...
    Medicine Products: